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Clinical
PET Facility
Returns to
M. D. Anderson

Nuclear Physicists
Continue Work Begun
During Camera's Absence

I
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by Kerry L. Wright
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ram 1994 until late last
year, T he University of
Texas M. D. Anderson
Cancer Center did not
have a working positron
emission tomography ( PET) camera,
but that did not stop its nuclear
physicists from making theoretical
advances in PET technology.
Now, after years of working behind
the scenes, their perseverance is
beginning to pay off.
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(Continued on next page)

After more than five years without a positron
emission tomography (PET) camera, M. D.
Anderson will soon open a new clinical PET center
directed by Dr. Homer Macapinlac (pictured),
an associate professor in the Department of
Nuclear Medicine.
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PET Facility Returns to M. D. Anderson
(Continued from page 1)

The Department of Nuclear Medicine recently forged a bond with
Russian scientists who are supplying
them with the rare earth materials they
need to make their theoretical improvements a reality. At the same time, a new
state-of-the-art clinical PET center is
being established.
The very first clinical PET camera
was constructed in the early 1970s at
the Mallinckrodt Institute of Radiology
at Washington University. According
to Edmund Kim, M.D., a professor in
the Department of Nuclear Medicine at
M. D. Anderson (and a nuclear medicine fellow at Washington University in
the 1970s), PET showed good promise
at the time, but its images were crude,
its use was mostly limited to imaging the
head, and its resolution was only about
20 mm. In 1987, the first PET camera
appeared at M. D. Anderson, where
Dr. Kim became the director of a new
clinical PET program, marking the
beginning of the institution's pioneering
use of PET in oncology.
While techniques such as magnetic
resonance imaging, computed tomography (CT), and ultrasonography are
used for anatomical studies (producing
images based on physical properties),
PET is a functional imaging technique
that takes advantage of the metabolic
abnormality of tumors. To perform PET,
a cyclotron ( or magnetic accelerator) is
used to radiolabel organic compounds,
such as glucose or amino acids, with
positron-emitting isotopes that are then
injected into a patient so that a metabolic image can be formed via a computer. Unfortunately, the metabolic
imaging center that M. D. Anderson
established in the 1980s closed in
the mid-1990s because operating the
cyclotron was very expensive, and
insurance companies often refused to
reimburse patients for clinical studies.
"Now there are almost 80 medical
centers with one or two PET scanners,"
said Dr. Kim. This huge boom has been
due in part to improvements in technology. For example, the computers of
today are smaller, cheaper, and more
efficient. In addition, the government
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"Our goal is to
develop really highresolution systems
at low cost."
-Wai-Hoi (Gary) Wong, Ph.D.,
professor, Department of
Nuclear Medicine

now allows reimbursement for clinical
PET studies: Three years ago, PET was
approved by Medicare for imaging
pulmonary nodules, lung cancer,
lymphoma, colorectal carcinoma,
and melanoma. On July 1, 2001, head
and neck and esophageal cancers will
be added to the list, and breast cancer
is the next disease to be evaluated.
While M. D. Anderson's metabolic
imaging center was closed, David J.
Yang, Ph.D., an associate professor
in the Department of Experimental
Nuclear Medicine, was working to
improve the radiolabeling process used
for PET. During that time, he created an
automated system that takes only 10 to
20 minutes per labeling reaction and is
currently being used at medical centers
in Japan. In addition, he is developing
a novel technique for labeling substrates
for single-photon emission CT (SPECT)
studies. In the new SPECT system,
substrates are labeled with technetium
instead of the isotopes used in PET,
and a gamma camera is used instead of a
PET camera. A chelator called ethylene
cysteine, or EC, is also used to help
conjugate the technetium to its substrate.
According to Dr. Yang, the beauty of
this new technique is that all substrates,
regardless of their chemistry, can be
labeled in the same way (which isn't
always the case for PET) using EC as a
common constituent in each reaction.
"So now we will have a universal rule for
looking at molecular targets," said Dr.
Yang.
Also busy at work while the PET
center was closed was a team of nine
physicists and electronic engineers led

by nuclear and PET physicist Wai-Hai
(Gary) Wong, Ph.D., a professor in the
Department of Nuclear Medicine,
who was conducting research to develop
cameras even more powerful than those
that were commercially available. The
team's most recent project is the
development of an eight-module
clinical camera designed to image not
only the head and whole body, as
current commercial cameras do, but
also the breast.
"Our goal is to develop really highresolution systems at low cost," said
Dr. Wong. The resolution, or the size
of a structure or lesion that can be seen,
is actually determined by the size of the
gamma ray detectors in the camera.
When positron-emitting isotopes enter
the body, they collide and react with
electrons to produce gamma ray photons
that strike the detectors. The detectors
then turn the light that is created into
electrical signals that are registered
by the computer to form an image.
Whereas cameras 15 years ago had
only 500 to 700 detectors, the model
Dr. Wong is working on has nearly
40,000 much smaller detectors and a
resolution of 2 mm for the head and
breast modes and 2 to 3 mm for the
whole-body mode, the highest resolution of any camera in the world. (The
most advanced commercial cameras
today have resolutions of 4 to 6 mm.)
According to Dr. Wong, one way
to reduce the cost of PET machines
( though possibly at the expense of
resolution) would be to reduce the
number of gamma ray detectors, which
are each made up of about 50 tiny
crystals resembling small jewels and are
the most expensive part of the machine.
"The second thing is to lower the price
of the crystals," he said. The crystals are
composed of rare earth materials found
predominantly in China and Russia. As
Russia is still in a state of perestroika,
the materials are much cheaper there,
said Dr. Wong, who recently traveled to
St. Petersburg, Moscow, and Siberia in
search of materials for his new model.
The nine-day trip resulted in an agreement with the Russian Academy of

Photos courtesy of Dr. Gary Wong

Dr. Wai-Hoi (Gary) Wong, a professor in the
Department of Nuclear Medicine, recently traveled to
the city of Novosibirsk in Siberia (above) in search of
rare earth materials to build a new high-resolution,
low-cost clinical PET camera. While there, Dr. Wong
met with representatives from the Institute of Inorganic
Chemistry at the Russian Academy of Science (right),
from whom he eventually purchased $1 00, 000 worth
of bismuth germinate crystals.
Science in Siberia to purchase $100,000
worth of bismuth germinate, currently
the most common material from which
the crystals are made. According to Dr.
Wong, if his team is satisfied with the
quality of the crystals and their model
camera is eventually produced, they
hope to create a long-standing relationship with their new partners in Russia.
As the efforts of Dr. Yang and Dr.
Wong continue, the Department of
Nuclear Medicine is also working hard
to reinstate its once-flourishing PET
facility. For the first time since the close
of the previous facility, a high-resolution
PET camera is in operation at M. D.
Anderson. The camera became active
in November 2000, and a new clinical
PET center will formally open on
May 10, 2001. According to Homer
Macapinlac, M.D., an associate professor and chief of the Section of Positron
Emission Tomography in the Department of Nuclear Medicine, about six
patients per day undergo PET imaging
in the facility, and its capacity has not
yet been reached. Dr. Macapinlac, who
is both developing and directing the
new center, recently joined M. D.
Anderson after spending the past five
years as clinical director of the PET

program at Memorial Sloan-Kettering
Cancer Center.
Data produced at Memorial SloanKettering and several other institutions
have shown that PET effectively
complements and in some ways even
exceeds the performance of other
traditional imaging systems. "PET
provides greater accuracy in diagnosing
disease, staging, determining the extent
of tumor present, and especially in
determining response to therapy,"
said Dr. Macapinlac.
According to Dr. Kim, conventional
imaging techniques often show abnormalities and morphological changes in
tumors after initial treatment, and PET
is particularly useful for differentiating
between posttreatment changes and
possible recurrences or irregular tumors.
To facilitate combining PET with
traditional imaging, a hybrid camera
will soon be purchased for M. D.
Anderson's new imaging center.
"The unit we're currently looking at
is actually a combined PET/CT unit,"
said Janet Champagne, the administrative manager of the Department of

Clinical Nuclear Medicine and the
coordinator for the center's formal
opening. "So you have one system
with one bed that the patient lies on.
They go through the CT, and then they
continue on and have the PET scan,"
she said. The images can then be fused
to display the functional and anatomical
data simultaneously.
The center is expected to have three
PET cameras in operation by the end of
2001, and additional growth will be
scheduled as necessary. "We're carefully
mapping the demand for PET images so
that we will have enough scanners and
cyclotrons to accommodate the projected clients," said Champagne. The
cameras will be available for any patient
within the institution and also for
patients outside the institution, upon
the request of their physicians. •
FOR MORE INFORMATION ' contact Dr. Kim
at (713) 794-1052, Dr. Yang at (713)
794-1053, Dr. Wong at (713) 792-5847,
or Dr. Macapinlac at (713) 792-7126.
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Postirradiation Oral Complications
Are Serious but Preventable
by Don Norwood

onsidering the threat
of postirradiation
oral complications,
the obvious question
is: Can they be prevented?
According to Mark Chambers,
D. M. D. , an assistant professor
of dental oncology in the
Department of Head and N eek
Surgery at The University of
Texas M. D. Anderson Cancer
Center, they can be, to a certain
extent, with the responsibility
resting in the hands of both
the patient and the medical
team.
As with other types of cancer
treatment, irradiation of head and neck
cancers produces toxic effects that can
be troublesome for patients and are
often serious enough to limit further
cancer treatment. One such effect is
dental deterioration, specifically
complications in the oral cavity of
patients who undergo irradiation of
head and neck cancers. While these
complications vary according to the
patient's oral status, type of malignancy,
and therapy combination (radiation
therapy with or without surgery,

Fluoride carriers such as this
customized fluoride chamber are
used to apply a fluoride gel to the
teeth of patients whose salivary
glands have been damaged
by radiation treatments and
who are susceptible to developing
dental caries .
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chemotherapy, or both), they are a
common problem.
"In most patients with cancer,
problems in the oral cavity mirror those
in the general population: moderate to
advanced periodontal disease, poorly
restored dentition, and soft tissue
pathologies associated with tobacco
use, alcohol use, nutritional neglect,
and general hygiene neglect," said Jack
Martin, D.D.S., professor and chief of
the Section of Oncologic Dentistry and
Prosthodontics in the Department of
Head and N eck Surgery. "Evaluation,
treatment, and prevention of oral and
dental pathology are important in the
overall treatment outcome of patients
with cancer."
The oral complications that occur
after radiation therapy are divided into
two classes: acute and long term.
Acute complications include mucositis,
infectious stomatitis, alteration of
taste and smell acuity, and dermatitis,
while long-term problems include
xerostomia, caries, abnormal development, fibrosis, trismus, photosensitivity,
and osteoradionecrosis. The severity
of these problems depends on many
factors, including the radiation dose, the
energy source, the volume of irradiated
tissue, and the patient's periodontal
condition and performance status.
"Irradiation can permanently destroy
cellular elements of bone, which can
limit the ability to heal after a traumatic
event," Dr. Chambers explained.
"Further, the risk of complications

following trauma or oral surgical
procedures in an irradiated field can
be highly significan t, although some
authors claim this risk is low up to a
predetermined thresh old of irradiation.
For these reasons, elective oral surgical
procedures such as extractions and soft
tissue surgery are contraindicated within
an irradiated field because of hypovascularity and hypocellularity. H owever, nonsurgical procedures that can
be safely performed include routine
restorative procedures , oral prophylaxis,
radiography, and en dodontic and
prosthodontic procedures."
Because certain surgical procedures
are not advised after radiation therapy,
dental oncologists examine patients
before treatment an d remove and
document any preex isting acute or
chronic pathologic conditions-dental
abscesses, teeth with advanced periodontal disease, dental calculus causing
gingivitis, partially erupted teeth with
potential for pericoronitis, and soft
tissue tooth trauma-that could affect
the cancer treatment strategy selected
by the treating physician.
One particularly troublesome aspect
of radiation therapy for head and neck
cancers is the effect it has on the
salivary glands. When these glands are
included in the volume of irradiated
tissue, the radiation causes atrophy of
the glands' secretory cells, leading to
a decrease in the quality and quantity
of salivary secretions. It has also been
postulated that radiation-induced
amage to t e g an s vascu ar an
connective tissues causes the decrease
in salivary secretions. Whatever the
cause, the effect is preventable.
"Salivary hypofunction can increase
the risk of dental caries, compromise
mucosal integrity, impair chewing and
swallowing, and reduce the quality of
life of irradiated patients," said Dr.
Chambers. "Therefore, when the
salivary glands are irreversibly damaged
from radiation therapy, the patient
can benefit from a well-documented
anticaries preventive regimen. This
regimen consists of a daily application
of 0.4% stannous fluoride gel or 1.0%

"If oral care
guidelines are
followed, oral tissues
can be maintained
in a healthy state
following radiation
therapy."
- Mark Chambers, D.M.D.,
assistant professor,
Department of Head
and Neck Surgery
Dr. Mark Chambers, an assistant professor of dental oncology in the Department
of Head and Neck Surgery, evaluates a simulation radiation film in preparation for oral
surgery on a patient with several oral abscesses who has completed radiation therapy.
sodium fluoride gel onto the dentition
using a brush-on techn ique or a vehicle
known as a fluoride carrier."
The 0.4% stann ous fluoride gel
( which was inven ted in a joint collaboration between M . D. A nderson and
the Veterans Administration Hospital
in Houston more than 40 years ago)
or 1.0% sodium fluoride gel is placed
in a custom-fabricated polypropylene
fluoride carrier, Dr. Ch ambers said. The
carrier is then placed onto the dentition,
completely covering and slightly extendin be ond the tooth surface, for 10
minutes; this is repeate ai y. Patients
who receive low radiation doses and are
expected to have slight xerostomia can
apply the gel using a toothbrush.
In addition to dental caries, irradiation of the salivary glands is associated
with other oral complications, particularly oral infections. "Changes in salivary
flow induced by radiation are worrisome
because saliva protects the oral mucosa
from dehydration and assists in removing
food and microbial debris from the oral
cavity," said Dr. Martin.
With guidance from the medical
team, however, patients can take

measures to prevent these complications, as well.
"To avoid oral infections and reduce
mucositis, the patient must frequently
rinse the oral cavity to reduce the
number of oral microorganisms and
maintain mucosal hydration. This can
be done with a solution of 1 teaspoon
of sodium bicarbonate in 1 quart of
water. This concoction should be used
frequently during each day to alkalinize
the oral cavity and keep the oral/
oropharyngeal tissues moist," said
Dr. Chambers.
gents t at promote t e flow of
saliva, such as cholinergic agonists,
have been investigated and shown to
have clinically significant benefits when
given for the symptomatic treatment of
postirradiation xerostomia. Other rinses
that are being investigated, such as
those containing cytokines, aloe vera
derivatives, and antibiotics, may prove
to be less irritating and more effective
in reducing the symptoms that occur
after radiation therapy.
Dr. Chambers noted that an exciting
development in the field of head and
neck cancer irradiation is intensity-

modulated radiation therapy (IMRT).
Currently used in the M. D. Anderson
Department of Radiation Oncology,
IMRT may reduce the total radiation
dose delivered to major salivary glands
in certain treatment schedules, which
would result in a reduction in the
incidence of postirradiation xerostomia.
While the advances in the treatment
of postirradiation oral complications are
encouraging, Dr. Martin stressed that
prevention remains the goal, the fulfillment of which should be a priority
for both patient and ractitioner.
"If oral care guidelines are followed,
oral tissues can be maintained in a
healthy state following radiation
therapy," Dr. Chambers said. "Cooperation and compliance are essential and
are the result of education and motivation ... By fostering communication and
compliance among the multidisciplinary
team, the practitioner can ensure that
patients with cancer of the head and
neck receive quality care." •
FOR MORE INFORMATION, contact
Dr. Chambers at (713) 792-2672
or Dr. Martin at (713) 745-2512.
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Trial Shows Pill Is as Effective
as Intravenous Chemotherapy
for Advanced Colon Cancer
by Julie Penne and Dawn Chalaire

atients with advanced
colorectal cancer may
soon have a less toxic,
more convenient
option for the treatment of their
disease-in the farm of a small
pink tablet.

candy lower incidence of diarrhea,
stomatitis, nausea, hair loss, and
neutropenia-symptom comm nly
associated with intravenou chemo
therapy. They al o required fewer trip
to the hospital for adver e reaction
than those taking 5-FU plus leucovorin.
But researcher ay the trade-off for
convenience is that patient mu t take
responsibility for taking the pill a
directed and for communicating
regularly with their health care team.
For that reason, the pill remains an
option, rather than a new standard
treatment, for patients with meta tatic
colon cancer.
"The encouraging results of thi
trial give physicians additional latitude
in recommending to each patient
the optimal course of treatment. It i
especially important to remember that
this oral drug was found to be equal to,
not superior to, the intravenous chemo
therapy regimen of 5-FU plu leucov
orin," said Robert Wolff, M.D., an
assistant professor in the Department
of Gastrointestinal Medical Oncology
and a colon cancer speciali t who
enrolled many patients in the trial.
"While the oral drug is much more
convenient for patients and produce
fewer side effects, this treatment

In a study led by The University of
Texas M. D. Anderson Cancer Center,
researchers found that oral capecitabine
(Xeloda) is an acceptable option to the
intravenous chemotherapy regimen of
fluorouracil (5-FU) plus leucovorin for
the treatment of metastatic colon cancer.
Investigators suggest, however, that
the oral drug is most appropriate for
patients who are highly motivated and
able to take multiple pills (usually three
or four) twice a day as recommended.
Results of the phase III trial, con
ducted at M. D. Anderson and 60
other sites throughout the United
States, Canada, Brazil, and Mexico,
are published in the April 15 issue of
the Joumal of Clinical Oncology. More
than 600 patients were enrolled in the
trial, all with colon cancer that had
spread to other organs.
According to the compara
tive study, tumors in approxio o patients w o
mate y
ers say
took the oral capecitabine
the trade-off for
responded, compared with
those in about 16% of patients
convenience is
receiving intravenous chemo
therapy. Median survival
that patients must
times were 12.5 months for
take responsibility
the oral drug and 13 .3 months
for the intravenous therapy,
for taking the pills
and median time to disease
progression was 4.3 months
as directed and for
for the pill and 4.7 months
communicating
for intravenous chemotherapy.
These differences were not
regularly with their
statistically significant.
Patients who took capecita
health care team.
bine experienced a signifi-

.
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"Thi tr atm nt i d finitely more
c nv ni nt and I toxic than thL
intravenou chem th rapy," aid Dr.
Wolff. "Bue it literally put the treat
ment in the hand f th pati nt.
It i a con ideration that physicians
mu t acknowl dg wh n d i ing a
treatment plan."
At the time th tudy wa de igncd,
intravenou 5-FU and leuc vorin \\a,
the tandard fir c-lin ch rapy for
advanced colorectal cancer. ince chu1,
a combination of 5-FU, 1 uc vorin, and
irinotecan ha become wid ly accepted
a the new tandard ther p .
"However, thi thr e-drug combina
ti n ha more p tential f, r toxicity than
5-FU and leucovorin al n . Th refore,
om phy ician , in di cu i n with
their patients, may elect to proceed
with oral therapy a fir t-line
treatment" Dr. Wolff aid.
Cap citabin , an oral
fluoropyrimidine carbamate
that i con erted to 5-FU
in tumor ti ue, i al o being
inve tigated in combination
with irinotecan in everal
clinical trial . Other tudie
are examining capecitabine
combined with oxaliplatin,
and pha e I trial of
irinotecan, oxaliplatin,
and capecitabine are
being planned. •
FOR MORE INFORMATION,

contact Dr. Wolff at
(713) 792-2828.

PET Facility Returns to M. D. Anderson
(Continued from page 1)

The Department of Nuclear Medicine recently forged a bond with
Russian scientists who are supplying
them with the rare earth materials they
need to make their theoretical improvements a reality. At the same time, a new
state-of-the-art clinical PET center is
being established.
The very first clinical PET camera
was constructed in the early 1970s at
the Mallinckrodt Institute of Radiology
at Washington University. According
to Edmund Kim, M.D., a professor in
the Department of Nuclear Medicine at
M. D. Anderson (and a nuclear medicine fellow at Washington University in
the 1970s), PET showed good promise
at the time, but its images were crude,
its use was mostly limited to imaging the
head, and its resolution was only about
20 mm. In 1987, the first PET camera
appeared at M. D. Anderson, where
Dr. Kim became the director of a new
clinical PET program, marking the
beginning of the institution's pioneering
use of PET in oncology.
While techniques such as magnetic
resonance imaging, computed tomography (CT), and ultrasonography are
used for anatomical studies (producing
images based on physical properties),
PET is a functional imaging technique
that takes advantage of the metabolic
abnormality of tumors. To perform PET,
a cyclotron (or magnetic accelerator) is
used to radiolabel organic compounds,
such as glucose or amino acids, with
positron-emitting isotopes that are then
injected into a patient so that a metabolic image can be formed via a computer. Unfortunately, the metabolic
imaging center that M. D. Anderson
established in the 1980s closed in
the mid-1990s because operating the
cyclotron was very expensive, and
insurance companies often refused to
reimburse patients for clinical studies.
"Now there are almost 80 medical
centers with one or two PET scanners,"
said Dr. Kim. This huge boom has been
due in part to improvements in technology. For example, the computers of
today are smaller, cheaper, and more
efficient. In addition, the government
2 I OncoLog

"Our goal is to
develop really highresolution systems
at low cost."
-Wai-Hoi (Gary) Wong, Ph.D.,
professor, Department of
Nuclear Medicine

now allows reimbursement for clinical
PET studies: Three years ago, PET was
approved by Medicare for imaging
pulmonary nodules, lung cancer,
lymphoma, colorectal carcinoma,
and melanoma. On July 1, 2001, head
and neck and esophageal cancers will
be added to the list, and breast cancer
is the next disease to be evaluated.
While M. D. Anderson's metabolic
imaging center was closed, David J.
Yang, Ph.D., an associate professor
in the Department of Experimental
Nuclear Medicine, was working to
improve the radiolabeling process used
for PET. During that time, he created an
automated system that takes only 10 to
20 minutes per labeling reaction and is
currently being used at medical centers
in Japan. In addition, he is developing
a novel technique for labeling substrates
for single-photon emission CT (SPECT)
studies. In the new SPECT system,
substrates are labeled with technetium
instead of the isotopes used in PET,
and a gamma camera is used instead of a
PET camera. A chelator called ethylene
cysteine, or EC, is also used to help
conjugate the technetium to its substrate.
According to Dr. Yang, the beauty of
this new technique is that all substrates,
regardless of their chemistry, can be
labeled in the same way (which isn't
always the case for PET) using EC as a
common constituent in each reaction.
"So now we will have a universal rule for
looking at molecular targets," said Dr.
Yang.
Also busy at work while the PET
center was closed was a team of nine
physicists and electronic engineers led

by nuclear and PET physicist Wai-Hoi
(Gary) Wong, Ph.D., a professor in the
Department of Nuclear Medicine,
who was conducting research to develop
cameras even more powerful than those
that were commercially available. The
team's most recent project is the
development of an eight-module
clinical camera designed to image not
only the head and whole body, as
current commercial cameras do, but
also the breast.
"Our goal is to develop really highresolution systems at low cost," said
Dr. Wong. The resolution, or the size
of a structure or lesion that can be seen,
is actually determined by the size of the
gamma ray detectors in the camera.
When positron-emitting isotopes enter
the body, they collide and react with
electrons to produce gamma ray photons
that strike the detectors. The detectors
then tum the light that is created into
electrical signals that are registered
by the computer to form an image.
Whereas cameras 15 years ago had
only 500 to 700 detectors, the model
Dr. Wong is working on has nearly
40,000 much smaller detectors and a
resolution of 2 mm for the head and
breast modes and 2 to 3 mm for the
whole-body mode, the highest resolution of any camera in the world. (The
most advanced commercial cameras
today have resolutions of 4 to 6 mm.)
According to Dr. Wong, one way
to reduce the cost of PET machines
( though possibly at the expense of
resolution) would be to reduce the
number of gamma ray detectors, which
are each made up of about 50 tiny
crystals resembling small jewels and are
the most expensive part of the machine.
"The second thing is to lower the price
of the crystals," he said. The crystals are
composed of rare earth materials found
predominantly in China and Russia. As
Russia is still in a state of perestroika,
the materials are much cheaper there,
said Dr. Wong, who recently traveled to
St. Petersburg, Moscow, and Siberia in
search of materials for his new model.
The nine-day trip resulted in an agreement with the Russian Academy of
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After Cancer: A Survivor's Diary
ancer survivors
often walk a fine
line between trying
to return to a
"normal" life and coping with
the legacy of their disease. The
following diary entries illustrate
some of the joys and challenges
encountered by cancer survi-vors, fallowed by helpful tips.

It's common for patients to feel
anxious about every checkup, and
this can last for several years. Arriving at
the appointment with a list of questions
can help you feel more in control.
Cancer checkups are a good time to ask
about the symptoms of recurrence, the
kind of diet that should be observed,
other treatment options, and other
concerns such as sexual problems, care
instructions, and general fitness.
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There are many ways around the
cancellation of health insurance.
Many states sell comprehensive health
insurance to state residents with serious
medical conditions who can't find a
company that will insure them. You
may also be able to enroll in a group plan.
Be careful about changing jobs until
you know whether you'll be covered
under the new company's group plan.
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Be on the watch for symptoms
that may indicate the return of your
cancer. Ask your physician what these
symptoms are, and be sure to follow your
oncologist's recommendations for
cancer screening tests.
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Eighty percent of people with
cancer return to work after diagnosis
and treatment. Research h as also shown
that cancer survivors are as productive
on their jobs as other workers, and
they aren't absent from work any more
frequently. Organizations such as the
Job Accommodation Network, the
National Coalition for Cancer Survivorship, and the Patient Advocate
Foundation can also help survivors
faced with employment issues.
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It is important to pace yourself,
especially right after cancer treatment.
Don't hesitate to say no to anything
that may be too demanding for you.
Be kind to yourself; focus on wh at you
can do and not on what you can't do.

~II

Do things that you enjoy once
your treatment is over, even if you
don't always feel your best. Pleasure is a
powerful tool!
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There is life after cancer!
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Consider joining a cancer survivors' group; it is a good place to learn
how to cope with problems unique to
your cancer or to the treatment you
received. M. D. Anderson's Life After
Cancer Care program ( www.mdanderson.
org/departments/lacc/) offers a Cancer
Survivor Message Board where cancer
survivors and their caregivers can
communicate, share concerns, and offer
encouragement.
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For more information , contact
your physician or contact the
M. D. Anderson Information Line:
({) (800) 392-1611 within

the United States, or
({) (713) 792-6161 in Houston

and outside the United States.
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